{"id":1867,"date":"2017-02-09T11:37:22","date_gmt":"2017-02-09T11:37:22","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1867"},"modified":"2021-07-24T12:56:39","modified_gmt":"2021-07-24T07:26:39","slug":"the-business-cocktail-10","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-10","title":{"rendered":"AMRI enters alliance; Ferring and Enteris deal; Quotient Clinical Acquires; Renova takes over Rights"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f3c41b9704a\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f3c41b9704a\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-10\/#AMRI_enters_alliance_with_Bruker_Daltonics_and_HighRes_Biosolutions\" >AMRI enters alliance with Bruker Daltonics and HighRes Biosolutions<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-10\/#Ferring_Pharmaceuticals_and_Enteris_BioPharma_enter_into_a_license_agreement\" >Ferring Pharmaceuticals and Enteris BioPharma enter into a license agreement<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-10\/#Quotient_Clinical_Acquires_SeaView_Research\" >Quotient Clinical Acquires SeaView Research<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-10\/#Renova_takes_over_Rights_of_stresscopin_from_Janssen\" >Renova takes over Rights of stresscopin from Janssen<\/a><\/li><\/ul><\/nav><\/div>\n<h3><span class=\"ez-toc-section\" id=\"AMRI_enters_alliance_with_Bruker_Daltonics_and_HighRes_Biosolutions\"><\/span>AMRI enters alliance with Bruker Daltonics and HighRes Biosolutions<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>AMRI has entered an alliance with Bruker Daltonics and HighRes Biosolutions to develop new applications for using high throughput mass spectrometry (MS) for drug discovery. AMRI has acquired the new MALDI PharmaPulse system from Bruker Daltonics and HighRes Biosolutions. The system will be deployed at AMRI&#8217;s Integrated Drug Discovery Center and, in accordance with the terms of the alliance, Bruker Daltonics and HighRes Biosolutions will provide training and consulting to AMRI biologists to aid them in their development of protocols on the system that can be used for high throughput screening drug discovery programs.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Ferring_Pharmaceuticals_and_Enteris_BioPharma_enter_into_a_license_agreement\"><\/span>Ferring Pharmaceuticals and Enteris BioPharma enter into a license agreement<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Ferring Pharmaceuticals and Enteris BioPharma have entered into a license agreement and initiated an early development agreement to leverage Enteris\u2019 proprietary and patented oral peptide and small molecule delivery platform, Peptelligence, to engineer an oral formulation of a peptide-based injectable therapeutic developed by Ferring. Enteris will license to Ferring its oral drug delivery technologies, as well as provide clinical trial finished product, and will receive milestones and royalties based on net sales of the developed product.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Quotient_Clinical_Acquires_SeaView_Research\"><\/span>Quotient Clinical Acquires SeaView Research<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Quotient Clinical has acquired SeaView Research with the aim of expanding its operations into the U.S. The acquisition combines Quotient and SeaView\u2019s complementary customer portfolios, and strengthens the early phase clinical experience of the combined business, enabling the company to deliver a broader set of services. Each of the facilities is capable of undertaking complex clinical research studies including first-in-human investigations.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Renova_takes_over_Rights_of_stresscopin_from_Janssen\"><\/span>Renova takes over Rights of stresscopin from Janssen<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Renova Therapeutics, gene therapy specialist, has signed an agreement to receive the investigational new drug (IND) file for stresscopin from Janssen Pharmaceuticals. Stresscopin is a hormone involved in responses to physiological stress and was previously under development at Janssen. Stresscopin has been shown in preclinical studies to protect cells exposed to fluctuating oxygen levels, such as occur in the heart in cardiovascular disease. Janssen&#8217;s scientists had previously\u00a0shown\u00a0that stresscopin and other related peptides can increase the ability of heart cells to contract. Renova will advance the programme development as RT-400, a peptide infusion treatment for episodes of acute decompensated heart failure (ADHF), which accounts for about half of all heart failure-related causes of hospitalization in the US.<\/p>\n<h3><\/h3>\n","protected":false},"excerpt":{"rendered":"<p>AMRI enters alliance with Bruker Daltonics and HighRes Biosolutions AMRI has entered an alliance with Bruker Daltonics and HighRes Biosolutions to develop new applications for using high throughput mass spectrometry (MS) for drug discovery. AMRI has acquired the new MALDI PharmaPulse system from Bruker Daltonics and HighRes Biosolutions. The system will be deployed at AMRI&#8217;s [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1254,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17438,715,17442,776,717,17441,17440,620,712,17439],"industry":[17225],"therapeutic_areas":[17242],"class_list":["post-1867","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-acquires-seaview-research","tag-acquisition","tag-amri","tag-business-cocktail","tag-collaboration","tag-enteris-biopharma","tag-ferring-pharmaceuticals","tag-merger","tag-pharma-industry","tag-quotient-clinical","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>AMRI enters alliance; Ferring and Enteris deal; Quotient Clinical Acquires<\/title>\n<meta name=\"description\" content=\"AMRI has entered an alliance with Bruker Daltonics and HighRes Biosolutions to develop new applications for using high.....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-10\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AMRI enters alliance; Ferring and Enteris deal; Quotient Clinical Acquires\" \/>\n<meta property=\"og:description\" content=\"AMRI has entered an alliance with Bruker Daltonics and HighRes Biosolutions to develop new applications for using high.....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-10\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-02-09T11:37:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/12053919\/1x-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"630\" \/>\n\t<meta property=\"og:image:height\" content=\"420\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AMRI enters alliance; Ferring and Enteris deal; Quotient Clinical Acquires","description":"AMRI has entered an alliance with Bruker Daltonics and HighRes Biosolutions to develop new applications for using high.....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-10","og_locale":"en_US","og_type":"article","og_title":"AMRI enters alliance; Ferring and Enteris deal; Quotient Clinical Acquires","og_description":"AMRI has entered an alliance with Bruker Daltonics and HighRes Biosolutions to develop new applications for using high.....","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-10","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-02-09T11:37:22+00:00","article_modified_time":"2021-07-24T07:26:39+00:00","og_image":[{"width":630,"height":420,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/12053919\/1x-1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-10","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-10","name":"AMRI enters alliance; Ferring and Enteris deal; Quotient Clinical Acquires","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-10#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-10#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/12053919\/1x-1.jpg","datePublished":"2017-02-09T11:37:22+00:00","dateModified":"2021-07-24T07:26:39+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"AMRI has entered an alliance with Bruker Daltonics and HighRes Biosolutions to develop new applications for using high.....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-10"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-10#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/12053919\/1x-1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/12053919\/1x-1.jpg","width":630,"height":420},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/12053919\/1x-1-300x200.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acquires SeaView Research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acquisition<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AMRI<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Business Cocktail<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Collaboration<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Enteris BioPharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ferring Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merger<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Quotient Clinical<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Acquires SeaView Research<\/span>","<span class=\"advgb-post-tax-term\">Acquisition<\/span>","<span class=\"advgb-post-tax-term\">AMRI<\/span>","<span class=\"advgb-post-tax-term\">Business Cocktail<\/span>","<span class=\"advgb-post-tax-term\">Collaboration<\/span>","<span class=\"advgb-post-tax-term\">Enteris BioPharma<\/span>","<span class=\"advgb-post-tax-term\">Ferring Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Merger<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>","<span class=\"advgb-post-tax-term\">Quotient Clinical<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Feb 9, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Feb 9, 2017 11:37 am","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1867"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1867\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1254"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1867"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1867"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}